Blood Peptide Signatures Could Predict Kidney Disease Progression Before Standard Tests Can
A mass spectrometry analysis of blood peptides identified 14 novel markers that distinguished kidney disease patients from healthy controls with 87% accuracy and correlated strongly with disease stage.
Quick Facts
What This Study Found
Using untargeted plasma peptidomics, researchers identified 14 peptide substances with concentrations that varied according to kidney function. Seven were most likely to be elevated in CKD patients. The peptidomic score model achieved an area under the curve of 0.87 (95% CI: 0.815-0.919; p < 0.0001), indicating strong diagnostic accuracy.
The score was significantly higher in CKD than non-CKD patients (2.539 ± 0.264 vs -0.938 ± 0.169). Remarkably, the model also predicted CKD stages with a Spearman correlation of 0.83 and concordance index of 0.899 (95% CI: 0.863-0.927). In univariate analysis, the peptidomic score was most strongly associated with C-reactive protein, sodium, and uric acid — substances not previously prioritized in CKD peptide research.
Key Numbers
How They Did This
Researchers performed untargeted plasma peptidomics on 172 subjects (66 non-CKD, 106 CKD at various stages) using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS). They applied LASSO logistic regression to select differentially expressed peptides and created a peptidomic scoring model. Selected peptides were identified and sequenced using MALDI-MS/MS. Univariate and multivariate analyses were performed to assess associations between the peptidomic score and clinical variables related to disease progression.
Why This Research Matters
Chronic kidney disease affects over 800 million people worldwide, and early detection of who will progress to kidney failure is one of the biggest unmet needs in nephrology. Current tests like creatinine and GFR are lagging indicators — by the time they change significantly, damage has already occurred. A blood peptide panel that can predict progression early could transform how kidney disease is monitored, enabling earlier intervention and potentially preventing dialysis for millions.
The Bigger Picture
This study exemplifies the growing field of peptidomics — using the body's peptide profile as a diagnostic fingerprint. While genomics and proteomics have received more attention, peptidomics captures a unique layer of biological information since many peptides are active signaling molecules or breakdown products that reflect real-time disease processes. Finding novel, previously unstudied peptide markers in CKD suggests that current understanding of kidney disease biology is incomplete, and these peptides could eventually become both diagnostic tools and therapeutic targets.
What This Study Doesn't Tell Us
This was a cross-sectional study, meaning it measured peptide levels at one point in time rather than tracking patients over years to see who actually progressed. The 14 identified peptides need validation in independent, larger cohorts. The study did not include a longitudinal component to confirm predictive power for disease progression. Some of the identified peptide markers were novel and their biological roles in CKD are not yet understood.
Questions This Raises
- ?Can these 14 peptide markers predict which early-stage CKD patients will progress to kidney failure when tracked over years?
- ?Are any of the novel peptide markers actively driving kidney disease progression, making them potential therapeutic targets?
- ?Could a clinical blood test based on this peptide panel be developed for routine kidney disease monitoring?
Trust & Context
- Key Stat:
- AUC = 0.87 The 14-peptide scoring model distinguished CKD from healthy controls with 87% accuracy — far better than many conventional markers for early kidney disease
- Evidence Grade:
- This is a cross-sectional biomarker discovery study with a reasonable sample size (n=172). The statistical results are strong, but the findings require validation in independent cohorts and longitudinal studies to confirm predictive value for disease progression.
- Study Age:
- Published in 2019, this study represents an early contribution to peptidomics-based CKD biomarker research. Validation studies in larger prospective cohorts would be needed to advance these markers toward clinical use.
- Original Title:
- Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.
- Published In:
- Journal of molecular medicine (Berlin, Germany), 97(10), 1451-1463 (2019)
- Authors:
- Gajjala, Prathibha R, Bruck, Heike, Noels, Heidi, Heinze, Georg, Ceccarelli, Francesco, Kribben, Andreas, Saez-Rodriguez, Julio, Marx, Nikolaus, Zidek, Walter, Jankowski, Joachim, Jankowski, Vera
- Database ID:
- RPEP-04177
Evidence Hierarchy
Frequently Asked Questions
Why can't regular blood tests predict kidney disease progression?
Standard markers like creatinine and estimated GFR measure current kidney function but are poor at predicting whether the disease will get worse. By the time these markers change significantly, substantial kidney damage has already occurred. Peptide biomarkers may detect disease-driving processes earlier because they reflect the body's active signaling and tissue breakdown in real time.
What is peptidomics and how is it different from proteomics?
Peptidomics is the study of all small protein fragments (peptides) in a biological sample, typically under 10,000 daltons. While proteomics examines whole proteins, peptidomics captures smaller signaling molecules and breakdown products that often serve as hormones, neurotransmitters, or markers of tissue damage. These peptide profiles can reveal disease processes that whole-protein analysis might miss.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04177APA
Gajjala, Prathibha R; Bruck, Heike; Noels, Heidi; Heinze, Georg; Ceccarelli, Francesco; Kribben, Andreas; Saez-Rodriguez, Julio; Marx, Nikolaus; Zidek, Walter; Jankowski, Joachim; Jankowski, Vera. (2019). Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.. Journal of molecular medicine (Berlin, Germany), 97(10), 1451-1463. https://doi.org/10.1007/s00109-019-01823-8
MLA
Gajjala, Prathibha R, et al. "Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.." Journal of molecular medicine (Berlin, 2019. https://doi.org/10.1007/s00109-019-01823-8
RethinkPeptides
RethinkPeptides Research Database. "Novel plasma peptide markers involved in the pathology of CK..." RPEP-04177. Retrieved from https://rethinkpeptides.com/research/gajjala-2019-novel-plasma-peptide-markers
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.